# Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors

> **NCT02016534** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 60 (actual)

## Conditions studied

- Stomach Neoplasms

## Interventions

- **DRUG:** AMG 337

## Key facts

- **NCT ID:** NCT02016534
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** Amgen decision following interim review of efficacy and safety data from the AMG 337 program.
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016534, "Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02016534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*